Background Production of the proatherogenic metabolite, trimethylamine N‐oxide (TMAO),
from dietary nutrients by intestinal microbiota enhances atherosclerosis development in …

Background Clinical studies implicate trimethylamine N‐oxide (TMAO; a gut microbiota‐
dependent nutrient metabolite) in cardiovascular disease risk. There is a lack of population …

Atherosclerosis remains the leading cause of death worldwide. Lifestyle modification,
including diet and exercise, is recommended to be the primary prevention strategy for …

Aims Gut microbiota and their generated metabolites impact the host vascular phenotype.
The metaorganismal metabolite trimethylamine N-oxide (TMAO) is both associated with …

Plasma trimethylamine N-oxide (TMAO) is associated with coronary atherosclerotic plaque
and cardiovascular disease risk, but associations between gut microbes in acute coronary …

Trimethylamine N-oxide (TMAO) is a circulating metabolite that has been implicated in the
development of atherosclerosis and cardiovascular disease (CVD). In this paper, we identify …

Atherosclerosis is the main cause of myocardial infarction and stroke, and the morbidity and
mortality rates of cardiovascular disease are among the highest of any disease worldwide …

Abstract Trimethylamine-N-oxide (TMAO) derived from the gut microbiota is an atherogenic
metabolite. This study investigates whether or not berberine (BBR) could reduce TMAO …

Host-microbiota interactions involving inflammatory and metabolic pathways have been
linked to the pathogenesis of multiple immune-mediated diseases and metabolic conditions …

Gut microbiota-derived metabolites have recently attracted considerable attention due to
their role in host-microbial crosstalk and their link with cardiovascular health. The MEDLINE …